Corbus Pharmaceuticals Holdings, Inc. (LON:0SZI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 113.05M +63.5% |
| Revenue (ttm) | n/a |
| Net Income | -64.01M |
| EPS | -4.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,658 |
| Open | 7.68 |
| Previous Close | 7.80 |
| Day's Range | 7.68 - 8.30 |
| 52-Week Range | 6.80 - 24.50 |
| Beta | 2.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About LON:0SZI
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts. [Read more]
News
Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two lead clinical assets are advancing: CRB-701 shows strong efficacy in HPV-positive oropharyngeal and cervical cancers, with pivotal studies aligned with FDA and a significant U.S. market opportunity. CRB-913 obesity data is expected in September, and cash runway extends into 2028.
Corbus Pharmaceuticals Holdings Transcript: KOL event
Panelists highlighted the rising incidence and unmet need in HPV-positive oropharyngeal cancer, emphasizing the promise of Nectin-4 ADCs like CRB-701 for this motivated patient group. Strategic trial design, manageable toxicity, and focused site selection are expected to drive rapid enrollment and strong clinical impact.
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
Wedbush lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $30 from $38 as the firm refines population assumptions in head and neck squamous cell carcinoma to reflect a…
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
Guggenheim views the weakness today in shares of Corbus Pharmaceuticals (CRBP) as overdone. The company’s CRB-701 data supports the drug’s “strong profile” in head and neck squamous cell carcinoma, th...
Corbus Pharmaceuticals Holdings Transcript: Study update
Updated ASCO data show strong efficacy and safety for CRB-701 in oropharyngeal head and neck and cervical cancers, with a 43% ORR in oropharyngeal and 34% in cervical at the top dose. Ocular toxicity is manageable, and the phase III TEMPO-1 trial will focus on oropharyngeal patients.
Corbus Pharmaceuticals Holdings Press release: Study update
Corbus Pharmaceuticals Holdings issued a press release on May 26, 2026, disclosing material business information to investors.
Corbus Pharmaceuticals Holdings Slides: Study update
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
Corbus Pharmaceuticals (CRBP) reported updated data from its Phase 1/2 clinical study of CRB-701. The new data demonstrate activity in the second line setting of two solid tumor types that…
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study (NCT0626...
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $44 from $40 and keeps an Outperform rating on the shares. The company surprised by announcing…
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2026
Upcoming ASCO presentations will provide mature efficacy and safety data for CRB-701 in cervical and head and neck cancers, guiding regulatory and clinical strategies. The obesity program CRB-913 has completed enrollment, with late summer data expected to clarify its competitive potential.
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Corbus Pharmaceuticals Holdings Transcript: AGM 2026
The meeting covered director elections, equity plan amendments, auditor ratification, and executive compensation votes. All proposals passed, including annual advisory votes on compensation. No questions were raised by stockholders.
Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer
Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $54 from $57 and keeps an Outperform rating on the shares following quarterly results. The firm is focused on…
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
Jefferies analyst Maury Raycroft lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $33 from $36 and keeps a Buy rating on the shares following the company’s Q1 update.
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapie...
Corbus Pharmaceuticals Holdings Earnings release: Q1 2026
Corbus Pharmaceuticals Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Corbus Pharmaceuticals Holdings Quarterly report: Q1 2026
Corbus Pharmaceuticals Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announ...
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target The company’s lead asset CRB-701 is in development for second-line head and neck…
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target